Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease, Eli Lilly issued a six-paragraph press release extolling the promise of an under-the-radar therapy of its own — one that, if effective, would seem to support Biogen’s claims as well. Now the world is about to see detailed data that will illuminate whether Lilly’s work offers reason for hope after years of frustration — or more equivocal evidence in the search for a treatment to slow the mental decline that marks Alzheimer’s.

Lilly will present the results of a small, Phase 2 study on its drug, donanemab, on March 13 at a virtual conference of Alzheimer’s researchers. Lilly said in January that the intravenous drug met its primary goal with a 32% improvement in cognition and function compared to placebo, a statistically significant difference, but researchers are reserving judgement until the company reveals key study details.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]